Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early Adcetris OK no surprise to SGEN after taking US FDA's advice

This article was originally published in Scrip

Executive Summary

The US FDA has been on a roll this month with approving cancer drugs ahead of schedule, with the latest being Seattle Genetics' Adcetris (brentuximab vedotin), the first therapy in 34 years available to treat patients with Hodgkin’s lymphoma (HL) – coming 11 days early, triggering a 14.2% jump in the Bothell, Washington-based biotech's stock on 19 August.


Related Content

One Down, Two To Go For Adcetris’ Expansion In Lymphoma


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts